Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.


Twist Bioscience IPO faces challenge from Agilent

Synthetic genetics company Twist Bioscience expects to go public this week, after raising around $280 million in venture capital funding.

What's new: Biotech giant Agilent, which previously employed Twist co-founder and CEO Emily Leproust, is seeking to make the IPO more difficult.

  • The two companies have been locked in litigation since early 2016, with Agilent claiming that Leproust stole trade secrets and improperly poached Agilent employees.
  • Twist has vigorously defended itself, insisting that its technology includes a key difference (namely the inclusion of silicone), and calling Agilent's lawsuit a baseless effort to “stifle innovation and competition."

Axios has learned that Agilent today plans to send a letter to the SEC, accusing Twist of making several false and misleading statements in its IPO filing documents. It also will ask the SEC to require Twist to make revisions.

  • Twist did file an amended S-1 document early this morning, but it did not seem to address any of Agilent's pending claims. For example, Twist says that Leproust co-founded and became CEO of the company in April 2013, but Agilent says that she acknowledged under oath to doing both more than a year earlier, while still employed at Agilent.

Bottom line: Twist has argued that Agilent is trying to disrupt its business. Agilent, by sending this letter just days before a scheduled IPO, is doing nothing to disabuse that notion — and holds more cards, given that there is no way for Twist to prove its case prior to pricing.

More stories loading.